Halozyme Begins Phase 2 Clinical Trials With Insulin Analogs Lispro And Aspart With RHuPH20 In Type 1 And Type 2 Diabetes
Links shared publicly online about this topic.
- 900total visits
Halozyme Begins Phase 2 Clinical Trials With Insulin Analogs Lispro And Aspart With RHuPH20 In Type 1 And Type 2 Diabetes
Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the
View full resource at medicalnewstoday.com
Tags: Diabetes Type 1 Medication, Diabetes Type 2 Medication, Diabetes Medication, Insulin, Phase 2 Clinical Trial, Clinical Trial, Lantus, Humalog
Most Recently Shared on September 3, 2010 at 5:00 pm By:
Halozyme Begins Phase 2 Clinical Trials With Insulin Analogs Lispro And Aspart With RHuPH20 In Type 1 And Type 2 Diabetes http://mnt.to/3Jfq
Also Shared By:
Advertisement
Scott Strumello
@sstrumello
RT @mnt_diabetes Halozyme Begins Phase 2 Clinical Trials With Insulin Analogs Lispro And Aspart Wi.. http://bit.ly/arqKXo
1 year ago...